ATE380556T1 - Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas - Google Patents

Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas

Info

Publication number
ATE380556T1
ATE380556T1 AT05757840T AT05757840T ATE380556T1 AT E380556 T1 ATE380556 T1 AT E380556T1 AT 05757840 T AT05757840 T AT 05757840T AT 05757840 T AT05757840 T AT 05757840T AT E380556 T1 ATE380556 T1 AT E380556T1
Authority
AT
Austria
Prior art keywords
lithiasis
gallbladder
pancreas
medication
kidney
Prior art date
Application number
AT05757840T
Other languages
English (en)
Inventor
Arbigny Pierre D
De Lassauniere Piere- Chabrier
Alan Bath Road Barcock
Original Assignee
Ipsen Ltd
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Ltd, Sod Conseils Rech Applic filed Critical Ipsen Ltd
Application granted granted Critical
Publication of ATE380556T1 publication Critical patent/ATE380556T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05757840T 2004-07-12 2005-07-06 Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas ATE380556T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0415490A GB2417419A (en) 2004-07-12 2004-07-12 Therapeutic use of Botulinum toxin

Publications (1)

Publication Number Publication Date
ATE380556T1 true ATE380556T1 (de) 2007-12-15

Family

ID=32865774

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05757840T ATE380556T1 (de) 2004-07-12 2005-07-06 Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas

Country Status (10)

Country Link
US (1) US7838009B2 (de)
EP (1) EP1773378B1 (de)
JP (1) JP4950044B2 (de)
AR (1) AR049977A1 (de)
AT (1) ATE380556T1 (de)
CA (1) CA2573441A1 (de)
DE (1) DE602005003836T2 (de)
ES (1) ES2297730T3 (de)
GB (1) GB2417419A (de)
WO (1) WO2006005912A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2509872T3 (es) 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CA2678038C (en) * 2007-02-15 2016-10-11 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US7455845B2 (en) * 1997-07-15 2008-11-25 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
WO2000001238A1 (en) * 1998-07-06 2000-01-13 Kajander E Olavi Methods for eradication of nanobacteria
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration

Also Published As

Publication number Publication date
US7838009B2 (en) 2010-11-23
EP1773378B1 (de) 2007-12-12
DE602005003836T2 (de) 2009-01-15
GB0415490D0 (en) 2004-08-11
DE602005003836D1 (de) 2008-01-24
GB2417419A (en) 2006-03-01
AR049977A1 (es) 2006-09-20
ES2297730T3 (es) 2008-05-01
EP1773378A2 (de) 2007-04-18
CA2573441A1 (en) 2006-01-19
JP2008505962A (ja) 2008-02-28
WO2006005912A2 (en) 2006-01-19
JP4950044B2 (ja) 2012-06-13
WO2006005912A3 (en) 2006-04-20
US20080292661A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
NO20080217L (no) B-celle reduksjon ved anvendelse av CD20-spesifikke bindingsmolekyler
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
ATE554091T1 (de) Aminotetrahydropyrane als dipeptidylpeptidase-iv- inhibitoren zur behandlung oder prävention von diabetes
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
DE602005026987D1 (de) Verfahren zur herstellung von 1,2-dichlorethan
ATE449771T1 (de) Azolylmethyloxirane, ihre verwendung zur bekämpfung von pflanzenpathogenen pilzen sowie sie enthaltende mittel
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
EP1934025A4 (de) Zusammensetzung zur behandlung von holz, verfahren zur behandlung von holz und holzprodukt
DE502006007963D1 (de) Verwendung von hydrophobinen zur schmutzabweisenden behandlung von harten oberflächen
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE602006019468D1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602006004680D1 (de) Maschine zur Herstellung von Mehrfachfiltern
DE602006003538D1 (de) Benzothiazol-, thiazolopyridin-, benzooxazol- und oxazolopyridin-derivate als verbindungen zur behandlung von diabetes
WO2006101387A3 (en) Method for interfering with blood coagulation by modulating cross-beta structures fibril formation
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
WO2005108428A3 (en) Cd40 splice variants and their uses
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
DE602004001627D1 (de) Methode zur Racemisierung von (S)-(+)- und (R)-(-)-10,11-Dihydro-10-hydroxy-5H-dibenzib,föazepine-5-carboxamiden und optisch angereicherten Mischungen davon
ATE380556T1 (de) Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
WO2006132739A3 (en) Novel chemical compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties